Pheochromocytomas and Paragangliomas Market Growth & Trends

The pheochromocytomas and paragangliomas market size is estimated to reach ~USD 660 million by 2034, registering a CAGR of 8.60% from 2025 to 2034, according to a new report by DelveInsight, a pharmaceutical market research firm. The rising incidence of rare neuroendocrine tumors and the expanding adoption of targeted therapies are the primary factors propelling market growth. Moreover, increasing advancements in HIF-2α inhibitors, peptide receptor radionuclide therapy (PRRT), and innovative radiopharmaceutical agents by pharma companies, including Merck, Novartis, Chimerix, Perspective Therapeutics, Bausch Health, Ono Pharmaceutical, and Ohara Pharmaceutical, among others, are driving the expansion of the pheochromocytomas and paragangliomas market.

The strong pheochromocytomas and paragangliomas clinical pipeline, demonstrating positive clinical results, is a major factor driving the PCPG therapeutic market. For instance, in May 2025, the FDA approved Merck's WELIREG (belzutifan), the first oral HIF-2α inhibitor, for treating adults and children aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL), marking a breakthrough in advanced PCPG treatment. The approval was based on the LITESPARK-015 trial demonstrating objective response rate.

The growing prevalence of pheochromocytomas and paragangliomas globally is further fueling market growth, as these rare neuroendocrine tumors arise from chromaffin cells. The total number of pheochromocytomas and paragangliomas incident cases in the 7MM was nearly 5K cases in 2024 and is projected to increase during the forecasted period. The United States accounts for approximately 61% of the total market share among 7MM. Among EU4 and the UK, Germany accounted for the highest number of incident cases, while Spain had the least number of cases.

Innovative treatment developments and regulatory approvals are also playing a crucial role in boosting market growth by expanding treatment options and improving patient outcomes. For instance, WELIREG (belzutifan) received FDA approval in May 2025, for the treatment of adult and pediatric patients (12 years and older) with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). Furthermore, in November 2024, Perspective Therapeutics presented initial results from its ongoing Phase I/IIa clinical trial of [212Pb] VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium.

Moreover, rising investments in precision oncology and genotype-driven therapies are providing lucrative opportunities for key Pheochromocytomas and Paragangliomas companies. The current treatment landscape has evolved significantly beyond surgical resection and symptomatic therapy with alpha-blockers and beta-blockers. Surgery remains the mainstay for localized PCPG, while systemic options remain scarce for advanced disease.

Request a free sample copy or view report summary: Pheochromocytomas and Paragangliomas Market Report

Pheochromocytomas and Paragangliomas Market Report Highlights

• To keep up with current market trends, DelveInsight takes KOLs and SME's opinions working in the domain through primary research to fill the data gaps and validate our secondary research. DelveInsight's analysts connected with 30+ KOLs to gather insights.
• The epidemiology chapter provides historical as well as forecasted epidemiology segmented by total incident cases of pheochromocytomas and paragangliomas, occurrence or absence of mutation in PCPG, age-specific cases of PCPG, and stage-specific cases of PCPG in the 7MM. It has been observed that germline/somatic mutations are present in nearly 75% of all cases in the US.
• The report provides an edge to pharma executives by understanding the market trends through SWOT analysis and expert insights, patient journey, and treatment preferences that help in shaping and driving the 7MM pheochromocytomas and paragangliomas market.
• The report contains an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, which will have an impact on the current treatment landscape.

Pheochromocytomas and Paragangliomas Market Segmentation

DelveInsight has segmented the pheochromocytomas and paragangliomas market based on therapy type, treatment line, end-user, and region:

Pheochromocytomas and Paragangliomas Treatment

• Surgery
• Symptomatic therapy (Alpha-blockers, Beta-blockers, Metyrosine)
• Chemotherapy
• Targeted therapy
• Radionuclide therapy
• Immunotherapy

Pheochromocytomas and Paragangliomas Drug Class Analysis

• HIF-2α Inhibitors
• Dopamine Receptor D2 (DRD2) Antagonists
• Peptide Receptor Radionuclide Therapy (PRRT)
• Radiopharmaceuticals

Pheochromocytomas and Paragangliomas Regional Outlook (Revenue, USD Million, 2025 - 2034)

• The United States
• Europe (Germany, France, Italy, Spain, the UK)
• Asia Pacific (Japan)

The pheochromocytomas and paragangliomas market is experiencing robust growth driven by technological advancements in targeted therapy, increasing disease prevalence, and an expanding pipeline of innovative treatments. The overall market is projected to grow significantly, driven by increasing genetic screening, better patient selection, and continued advancements in HIF-2α inhibitors, radioligand therapies, and novel targeted constructs. The PCPG pipeline features genotype-driven TKIs, radioligand therapies, and novel targeted constructs, with momentum led by biotech innovators and academic consortia.

The comprehensive DelveInsight pheochromocytomas and paragangliomas market report provides pharmaceutical executives with the detailed market intelligence, competitive analysis, and strategic insights necessary to navigate this complex and rapidly evolving therapeutic landscape.